Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.18B | $22.49M | $0.46 |
| 2024 | $2.03B | $43.15M | $0.91 |
| 2023 | $1.39B | $60.72M | $1.30 |
| 2022 | $1.14B | $45.17M | $1.00 |
| 2021 | $773.91M | $68.92M | $1.57 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.36 per share
Typical surprise -39.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.40 vs $0.34beat
- Thu, May 7$0.30 vs $0.29beat
- Mon, Mar 2$0.54 vs $0.15beat
- Thu, Nov 6$0.01 vs $0.47miss
- Thu, Aug 7$0.19 vs $0.36miss
- Thu, May 8$0.14 vs $0.23miss
Estimates and results for ASTH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ASTH's reported EPS growth of -26.4% a year over 4 years. Historical EPS growth of -26% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.20
- Implied price
- $10.98
- Return from $40.81
- -23.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5.46 — -86.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 38 | 46 | 54 | 62 | 70 |
|---|---|---|---|---|---|
| -25.0% | -36.7% | -34.3% | -32.1% | -30.2% | -28.5% |
| -20.0% | -32.5% | -29.9% | -27.6% | -25.6% | -23.8% |
| -15.0% | -28.3% | -25.5% | -23.1% | -20.9% | -19.0% |
| -10.0% | -24.1% | -21.1% | -18.6% | -16.3% | -14.2% |
| -5.0% | -19.9% | -16.8% | -14.0% | -11.6% | -9.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsseekingalpha.com·3d ago·Positive
Astrana Health: 81% Full-Risk And Profitable Astrana Health is rated a buy, trading at a 46% discount to peers despite sector-wide reserve releases clarifying earnings quality concerns. ASTH's Care Enablement platform drove G&A costs from 7.75% to 5.57% of revenue, quadrupling third-party revenue year-over-year and supporting durable profit at scale. Organic growth is driven by a mix-shift into full-risk capitation, with management projecting ongoing revenue-per-member expansion and a robust con
View source ↗